Tirzepatide
MetabolicAlso known as GIP/GLP-1 dual agonist
Evidence tier
Regulator-reviewed human evidence
4 human trials · 1 review · approved counterpart
- Researched since
- 2018
- Publications
- 2.3k
- Mean purity
- 99.8%
- Vendors listing
- 12
Ascension Peptides shows the highest mean assayed purity for Tirzepatide at 99.9% across 2 lot records. Purity figures below come from the certificates named in each row.
Score breakdown
The score has two halves: the research base — how long the compound has been studied and how much has been published — and the quality of the evidence the market produces for it, aggregated across every vendor that carries it: assayed purity, lot-to-lot consistency, readable third-party certificates and those vendors’ review record. It measures the evidence base, not the merits or safety of the substance.
Studied since 2018 — 8 years of published research
How long the compound has been studied. Fifteen years or more of published literature earns full marks; a newer compound earns less.
2,326 publications indexed in PubMed
The volume of published literature located. Full marks at fifty or more publications.
Mean assayed purity 99.8% across 42 certificates
Average assayed purity on the certificates published by vendors that carry this compound. Full marks at 99.5%+, nothing at 95% or below.
±0.16 pts purity across lots, mean label deviation 10.5%
How tightly assayed purity and labeled-versus-actual mass hold across different lots. Rewards reproducible manufacturing.
12 of 12 listing vendors publish an accessible certificate policy
Whether the vendors carrying this compound publish per-lot certificates anyone can read without an account.
40 of 42 certificates from a recognised independent lab
Share of certificates issued by a recognised third-party testing lab rather than an unnamed or self-named one.
What is Tirzepatide?
A dual GIP and GLP-1 receptor agonist peptide. As with semaglutide, an approved pharmaceutical product exists; material listed by indexed vendors is research-grade powder and is not that product.
Studied in published research for type 2 diabetes and obesity / weight management.
Regulatory status
Approved as a prescription medicine in several jurisdictions. Research-grade material listed by indexed vendors is labeled for laboratory research use only.
What the research examines
The areas of published research this compound appears in. These describe what the literature has studied — never a claim of benefit, effect or suitability for any use.
Published research
A published clinical literature exists for the approved pharmaceutical product. It does not transfer to research-grade material, whose identity and purity depend entirely on the certificate accompanying the lot.
- Tirzepatide for Obesity Treatment and Diabetes Prevention — The New England journal of medicine (2025)
Peer-reviewed article indexed in PubMed, published in The New England journal of medicine (2025).
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity — The New England journal of medicine (2025)
Peer-reviewed article indexed in PubMed, published in The New England journal of medicine (2025).
- Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis — The New England journal of medicine (2024)
Peer-reviewed article indexed in PubMed, published in The New England journal of medicine (2024).
- Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial — JAMA (2024)
Peer-reviewed article indexed in PubMed, published in JAMA (2024).
- Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity — JAMA internal medicine (2024)
Peer-reviewed article indexed in PubMed, published in JAMA internal medicine (2024).
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial — Lancet (London, England) (2021)
Peer-reviewed article indexed in PubMed, published in Lancet (London, England) (2021).
- Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight — Diabetes, obesity & metabolism (2025)
Peer-reviewed article indexed in PubMed, published in Diabetes, obesity & metabolism (2025).
- Tirzepatide: A Review in Type 2 Diabetes — Drugs (2024)
Peer-reviewed article indexed in PubMed, published in Drugs (2024).
Indexed studies5 human-evidence of 5
- Meta-analyses of GLP-1 receptor agonist trials — Meta-analysis
Placeholder seed record. Pooled analyses of trials of approved GLP-1 receptor agonist products. Meta-analytic findings inherit the population and product of the trials they pool, and do not transfer to material obtained outside that supply chain.
- Randomised controlled trials of tirzepatide, the approved medicine — Human — controlled trial
Placeholder seed record. Trial literature for the approved dual GIP/GLP-1 agonist product. As with semaglutide, the evidence attaches to the approved product rather than to research-grade powder of unverified identity.
- Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity — Human — controlled trial, 2024
Obstructive sleep apnea is characterized by disordered breathing during sleep and is associated with major cardiovascular complications; excess adiposity is an etiologic risk factor. Tirzepatide may be a potential treatment. We conducted two phase 3, double-blind, randomized, controlled trials involving adults with moderate-to-severe obstructive sleep apnea and obesity. Participants who were not receiving treatment with positive airway pressure (PAP) at baseline were enrolled…
- Tirzepatide Once Weekly for the Treatment of Obesity — Human — controlled trial, 2022
Obesity is a chronic disease that results in substantial global morbidity and mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, in people with obesity are not known. In this phase 3 double-blind, randomized, controlled trial, we assigned 2539 adults with a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or more, or 27 or more a…
- Tirzepatide for Obesity Treatment and Diabetes Prevention — Human — controlled trial, 2025
Obesity is a chronic disease and causal precursor to myriad other conditions, including type 2 diabetes. In an earlier analysis of the SURMOUNT-1 trial, tirzepatide was shown to provide substantial and sustained reductions in body weight in persons with obesity over a 72-week period. Here, we report the 3-year safety outcomes with tirzepatide and its efficacy in reducing weight and delaying progression to type 2 diabetes in persons with both obesity and prediabetes. We perfor…
Evidence digest
What the research on Tirzepatide actually shows
The indexed literature on Tirzepatide includes human clinical or observational records (5 human-clinical or observational records). This digest describes the shape of that evidence and links the records behind it. It does not judge whether Tirzepatide is safe or effective for any purpose, and nothing here is medical advice — the material sold by the vendors in this index is labeled for laboratory research use only.
3 things the literature does not establish →
PepIndex describes what literature exists. We do not interpret it, assess clinical significance, or publish quantities, protocols or instructions for use.
Vendor comparison
| Vendor | Score here | Price / mg | Certificates | Mean purity | Label deviation | Get it |
|---|---|---|---|---|---|---|
| Next Gen PeptidesISO/IEC 17025 | 93.897% | — | 1 | 99.9% | 5.6% | |
| American PeptidesISO/IEC 17025 | 92.9100% | $3.33 (68%) | 5 | 99.9% | 3.8% | |
| PeptidePlugs | 89.790% | — | 3 | 99.9% | 3.6% | |
| Hydro Research PeptidesISO/IEC 17025 | 88.289% | — | 7 | 99.7% | 13.0% | |
| Prime PeptidesISO/IEC 17025 | 87.180% | — | 3 | 99.9% | 8.6% | |
| Northline LabsISO/IEC 17025 | 79.493% | — | 1 | 99.3% | 2.2% | |
| ZC Labs | 79.384% | — | 2 | 99.5% | 12.0% | |
| Ascension Peptides | 78.186% | — | 2 | 99.9% | 13.1% | |
| Disguised Alpha | 75.370% | $3.17 (65%) | 0 | — | — | |
| Polaris PeptidesISO/IEC 17025 | 7597% | $9.00 (183%) | 16 | 99.8% | 14.4% | |
| Vertex Labs | 70.170% | — | 2 | 99.7% | 2.7% | |
| Evolve Peptides | 59.667% | $6.50 (132%) | 0 | — | — |
Certificate records
| Vendor | Lot | Tested | Lab | Labeled | Assayed | Discrepancy | Purity | Source |
|---|---|---|---|---|---|---|---|---|
| PeptidePlugs | 22130L-DK | Freedom Diagnostics Testing | 30 mg | 30.12 mg | 0.4% | 99.9% | Vendor-published | |
| ZC Labs | ZCLa2607290144 | Freedom Diagnostics Testing | 10 mg | 11.69 mg | 16.9% | 99.4% | Vendor-published | |
| Prime Peptides | 26070902 | Analysis FreedomDiagnostics | 30 mg | 31.2 mg | 4.0% | 100.0% | Vendor-published | |
| Prime Peptides | 26070201 | Analysis FreedomDiagnostics | 30 mg | 34.1 mg | 13.7% | 99.9% | Vendor-published | |
| Hydro Research Peptides | HR-2026-3814 | ILS Laboratories | 10 mg | 10.48 mg | 4.8% | 99.8% | Vendor-published | |
| Vertex Labs | 2607010626 | Freedom Diagnostics Testing | 10 mg | 9.73 mg | 2.7% | 99.7% | Vendor-published | |
| Vertex Labs | 072026 | Analysis FreedomDiagnostics | 10 mg | 9.73 mg | 2.7% | 99.7% | Vendor-published | |
| American Peptides | TIR100-0616 | Bioviridian Inc. | 100 mg | 101.25 mg | 1.3% | 99.9% | Vendor-published | |
| American Peptides | TIR20-0528 | Bioviridian Inc. | 20 mg | 20.38 mg | 1.9% | 99.9% | Vendor-published | |
| American Peptides | TIR10-0528 | Bioviridian Inc. | 10 mg | 10.42 mg | 4.2% | 99.9% | Vendor-published | |
| American Peptides | TIR600-0528 | Bioviridian Inc. | 60 mg | 60.57 mg | 1.0% | 99.9% | Vendor-published | |
| PeptidePlugs | Clear Cap/Silver Crimp | Freedom Diagnostics Testing | 60 mg | 59.37 mg | 1.1% | 100.0% | Vendor-published | |
| ZC Labs | ZCLa2606080088 | Freedom Diagnostics Testing | 40 mg | 42.81 mg | 7.0% | 99.7% | Vendor-published | |
| Next Gen Peptides | TRZ30-13 | ILS Laboratories | 30 mg | 31.68 mg | 5.6% | 99.9% | Vendor-published | |
| Polaris Peptides | P2L-T30-19 | BTLabs | 30 mg | 37.4 mg | 24.7% | 99.6% | Vendor-published | |
| Northline Labs | NLL-9887337 | Northline Labs | 10 mg | 10.22 mg | 2.2% | 99.3% | Vendor-published | |
| Polaris Peptides | POL-T30-18 | TrustPointe Analytics LLC | 30 mg | 34.13 mg | 13.8% | 99.9% | Vendor-published | |
| Prime Peptides | 3122026TR | Bioviridian Inc. | 10 mg | 10.82 mg | 8.2% | 99.8% | Vendor-published | |
| American Peptides | TIRZ10-0318 | Excellence in HPLC-MS Analysis | 10 mg | 11.06 mg | 10.6% | 99.8% | Vendor-published | |
| Hydro Research Peptides | HRP-99314 | ILS Laboratories | 60 mg | 68.98 mg | 15.0% | 99.8% | Vendor-published | |
| Hydro Research Peptides | HRP-59013 | ILS Laboratories | 10 mg | 11.48 mg | 14.8% | 99.7% | Vendor-published | |
| Hydro Research Peptides | HRP-44276 | ILS Laboratories | 100 mg | 110.64 mg | 10.6% | 99.9% | Vendor-published | |
| Hydro Research Peptides | HRP-26784 | Janoshik Laboratory | 15 mg | 17.34 mg | 15.6% | 99.7% | Vendor-published | |
| Hydro Research Peptides | HRP-81539 | Laboratory Name Not Provided | 30 mg | 35.05 mg | 16.8% | 99.9% | Vendor-published | |
| Hydro Research Peptides | HRP-72846 | ILS Laboratories | 5 mg | 5.66 mg | 13.2% | 99.4% | Vendor-published | |
| Polaris Peptides | POL-T10-18 | TrustPointe Analytics LLC | 10 mg | 11.25 mg | 12.5% | 99.6% | Vendor-published | |
| PeptidePlugs | 005-B | Freedom Diagnostics Testing | 30 mg | 32.79 mg | 9.3% | 99.8% | Vendor-published | |
| Polaris Peptides | POL-T10-17 | TrustPointe Analytics LLC | 10 mg | 11.8 mg | 18.0% | 99.8% | Vendor-published | |
| Ascension Peptides | 35-01260229 | MZ Biolabs | 30 mg | 33.42 mg | 11.4% | 100.0% | Vendor-published | |
| Ascension Peptides | 05-01260229 | MZ Biolabs | 10 mg | 11.47 mg | 14.7% | 99.9% | Vendor-published | |
| Polaris Peptides | SPL-2586 | TrustPointe Analytics LLC | 60 mg | 67.98 mg | 13.3% | 99.8% | Vendor-published | |
| Polaris Peptides | POL-T30-17 | TrustPointe Analytics LLC | 30 mg | 34.58 mg | 15.3% | 100.0% | Vendor-published | |
| Polaris Peptides | POL-T-30-16 | TrustPointe Analytics LLC | 30 mg | 36.28 mg | 20.9% | 99.9% | Vendor-published | |
| Polaris Peptides | POL-T50-4 | TrustPointe Analytics LLC | 50 mg | 58.3 mg | 16.6% | 99.5% | Vendor-published | |
| Polaris Peptides | POL-T30-15 | TrustPointe Analytics LLC | 30 mg | 36.71 mg | 22.4% | 99.7% | Vendor-published | |
| Polaris Peptides | POL-T50-3 | TrustPointe Analytics LLC | 50 mg | 51.08 mg | 2.2% | 99.9% | Vendor-published | |
| Polaris Peptides | POL-T5-6 | TrustPointe Analytics LLC | 5 mg | 5.44 mg | 8.8% | 99.7% | Vendor-published | |
| Polaris Peptides | POL-T30-11 | TrustPointe Analytics LLC | 30 mg | 32.94 mg | 9.8% | 99.9% | Vendor-published | |
| Polaris Peptides | POL-T10-13 | TrustPointe Analytics LLC | 10 mg | 11.91 mg | 19.1% | 99.8% | Vendor-published | |
| Polaris Peptides | POL-T10-10 | TrustPointe Analytics LLC | 10 mg | 11.01 mg | 10.1% | 99.6% | Vendor-published | |
| Polaris Peptides | SPL-0377-R01 | TrustPointe Analytics LLC | 10 mg | 11.15 mg | 11.5% | 99.7% | Vendor-published | |
| Polaris Peptides | POL-T10-11 | TrustPointe Analytics LLC | 10 mg | 11.22 mg | 12.2% | 99.9% | Vendor-published |